tiprankstipranks
iKena Oncology reports Q3 EPS (21c), consensus (27c)
The Fly

iKena Oncology reports Q3 EPS (21c), consensus (27c)

As of September 30, 2024, the Company had cash, cash equivalents, and marketable securities of $138.0 million.

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App